Anti-epidermal growth factor receptor monoclonal antibodies as potential anti-cancer agents

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• The epidermal growth factor (EGF) receptor is overexpressed in many human tumors.
• EGF receptor signaling is implicated in autocrine tumor cell growth.
• Targeting the EGF receptor presents a potential strategy for cancer therapy.

Purpose of the Study:

• To evaluate the efficacy of anti-EGF receptor monoclonal antibodies (MAbs) in inhibiting tumor cell growth.
• To assess the in vivo behavior and toxicity of anti-EGF receptor MAbs in a Phase I clinical trial.

Main Methods:

• In vitro studies using anti-EGF receptor MAbs to block ligand binding and assess effects on EGF/TGF-alpha stimulated cells.
• In vivo studies evaluating the inhibition of human tumor xenograft growth.
• A Phase I clinical trial administering anti-EGF receptor MAb to patients with squamous cell carcinoma of the lung.

Main Results:

• Anti-EGF receptor MAbs effectively prevented the growth of EGF/TGF-alpha-stimulated cells in culture.
• Significant inhibition of human tumor xenograft growth was observed in models with high EGF receptor levels.
• A single dose of 120 mg anti-EGF receptor MAb localized to tumors and maintained therapeutic blood concentrations for over 3 days without toxicity in lung cancer patients.

Conclusions:

• Anti-EGF receptor MAbs are effective in inhibiting tumor cell proliferation both in vitro and in vivo.
• Phase I trial data indicate that anti-EGF receptor MAbs can safely reach target tumors and achieve sustained therapeutic levels.
• Targeting the EGF receptor with MAbs represents a viable therapeutic approach for specific human malignancies.